RPS 1316 - Advanced imaging for oncology staging and follow-up
Lectures
1
Introduction by the moderator
02:00Marius E. Mayerhöfer, Vienna / AT
2
A novel non-invasive approach to cancer of unknown primary: AI can detect CT morphological differences between primary tumours and metastases across tumour types
08:00Zuhir Elkarghali, Amsterdam / NL
3
Magnetic resonance imaging (MRI) for staging melanoma patients in direct comparison to computed tomography (CT): results from a prospective positron-emission tomography PET/CT and PET/MRI study
08:00Cecilia Zhang, Tuebingen / DE
4
Identification of early CT imaging response predictors after CAR T-cell therapy
08:00Michael Winkelmann, Munich / DE
5
CT‑based radiomics score of PET-negative residual CT Masses: a potential biomarker for the prediction of relapse‑free survival in lymphoma patients showing complete metabolic response
08:00Seung Ha Cha, Seoul, Seocho-gu / KR
6
Preliminary whole-body MRI study for evaluation of minimal residual disease in a group of multiple myeloma patients
08:00Valentina Angelini, Napoli / IT
7
Ultra low dose whole-body computed tomography protocol optimisation for patients with plasma cell disorders: diagnostic accuracy and effective dose analysis from a reference centre
08:00Davide Tore, Asti / IT
8
Iodine quantification on multi-vendor DECT platforms: inter-scanner variability and impact of normalisation
08:00Simon Lennartz, Köln / DE
9
Investigating the validity of computed tomography low dose simulations in a prospective intra-individual in-vivo real low dose animal study on a 3rd generation dual-source scanner
08:00Andreas Brendlin, Tübingen / DE
10
Optimal keV in virtual monoenergetic imaging reconstructions for the detection of hypovascularized liver metastases on a novel photon counting dual-source CT scanner: initial experience
08:00Josua Decker, Augsburg / DE
11
Feasibility and dose evaluation of a dynamic liver perfusion CT protocol with latest generation scanner